ARS Pharmaceuticals SPRY
NASDAQ SPRY
$5.68 +0.01 (+0.18%)
As of: Sep 4, 2026 · 3:16 PM EDT

ARS Pharmaceuticals (SPRY) Gross Profit (2024 - 2026)

Analysis

ARS Pharmaceuticals (SPRY) Gross Profit (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.51 Bn 130.66 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.24 Bn 77.25 Bn 3.93 Bn
3 Argenx Se 63.46 Bn 58.28 Bn 1.37 Bn
4 Moderna 57.89 Bn 52.75 Bn 52.00 Mn
5 Revolution Medicines 44.02 Bn 44.02 Bn -
6 BeOne Medicines 39.95 Bn 34.85 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.49 Bn 32.19 Bn 992.69 Mn
8 Royalty Pharma 28.43 Bn 27.59 Bn -
9 Insmed 27.39 Bn 26.22 Bn 358.27 Mn
10 ARS Pharmaceuticals 564.59 Mn 420.75 Mn 20.81 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 20.81 Mn
Mar 31, 2026 16.40 Mn
Dec 31, 2025 21.93 Mn
Sep 30, 2025 24.31 Mn
Jun 30, 2025 10.73 Mn
Mar 31, 2025 6.88 Mn
Dec 31, 2024 85.72 Mn
Sep 30, 2024 1.96 Mn
Jun 30, 2024 500,000.00